IP Library › Granted Patent US 10,822,340

Granted Patent B2

US 10,822,340 · App. 16/149,606 · Granted Nov 3, 2020

Substituted imidazolopyrazine compounds and methods of using same

Inventors: Bradley J. Backes (San Francisco, CA); Dustin J. Maly (Seattle, WA); Scott A. Oakes (San Francisco, CA); Feroz R. Papa (San Francisco, CA); Gayani Perera (Nugegoda, LK); Likun Wang (San Francisco, CA)

Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

C07D487/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,822,340
App. No.: 16/149,606
Granted: Nov 3, 2020
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Described herein, inter alia, are certain substituted imidazolopyrazines of formula (I) and methods of using the same for modulating the activity of Ire1.

Claims (116)

1. A compound having the formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

ring A is R 41 -substituted or unsubstituted cycloalkylene, R 41 -substituted or unsubstituted heterocycloalkylene, R 41 -substituted or unsubstituted arylene, or R 41 -substituted or unsubstituted heteroarylene;

L 1 is a bond or unsubstituted C 1 -C 5 alkylene;

L 2 is —NR 6a —;

R 1 is halogen, —CX 3 , —CN, —S(O) 2 Cl, —S(O) n R 10 , —S(O) v NR 7 R 8 , —NHNH 2 , —ONR 7 R 8 , —NHC(O)NHNH 2 , —NHC(O)NR 7 R 8 , —N(O) m , —NR 7 R 8 , —C(O)OR 9 , —OR 10 , —NR 7 S(O) n R 10 , —NR 7 C(O)R 9 , —NR 7 C(O)OR 9 , —NR 7 OR 9 , —OCX 3 , —OCHX 2 , R 11 -substituted alkyl, R 11 -substituted or unsubstituted cycloalkyl, R 11 -substituted or unsubstituted heterocycloalkyl, R 11 -substituted aryl, or R 11 -substituted or unsubstituted heteroaryl;

R 2 is hydrogen, halogen, —CX a 3 , —CN, —S(O) 2 Cl, —S(O) n1 R 10a , —S(O) v1 NR 7a R 8a , —NHNH 2 , —ONR 7a R 8a , —NHC(O)NHNH 2 , —NHC(O)NR 7a R 8a , —N(O) ml , —NR 7a R 8a , —C(O)R 9a , —C(O)OR 9a , —C(O)NR 7a R 8a , —OR 10a , —NR 7a S(O) n1 R 10a , —NR 7a C(O)R 9a , —NR 7a C(O)OR 9a , —NR 7a OR 9a , —OCX a 3 , —OCHX a2 , R 14 -substituted or unsubstituted alkyl, R 14 -substituted or unsubstituted heteroalkyl, R 14 -substituted or unsubstituted cycloalkyl, R 14 -substituted or unsubstituted heterocycloalkyl, R 14 -substituted or unsubstituted aryl, or R 14 -substituted or unsubstituted heteroaryl;

each R 3 is independently hydrogen, halogen, —CX b3 , —CN, —S(O) 2 Cl, —S(O) n2 R 10b , —S(O) v2 NR 7b R 8b , NHNH 2 , —ONR 7b R 8b , —NHC(O)NHNH 2 , —NHC(O)NR 7b R 8b , —N(O) m2 , —NR 7b R 8b , —C(O)R 9b , —C(O)OR 9b , —C(O)NR 7b R 8b , —OR 10b , —NR 7b S(O) n2 R 10b , —NR 7b C(O)R 9b , —NR 7b C(O)OR 9b , —NR 7b OR 9b , —OCX b 3 , —OCHX b 2 , R 17 -substituted or unsubstituted alkyl, R 17 -substituted or unsubstituted heteroalkyl, R 17 -substituted or unsubstituted cycloalkyl, R 17 -substituted or unsubstituted heterocycloalkyl, R 17 -substituted or unsubstituted aryl, or R 17 -substituted or unsubstituted heteroaryl;

R 4 is hydrogen or unsubstituted C 1 -C 6 alkyl;

R 5 is hydrogen or unsubstituted C 1 -C 6 alkyl;

R 7 , R 8 , R 9 , R 10 , R 6a , R 7a , R 8a , R 9a , R 10a , R 7b , R 8b , R 9b , and R 10b are each independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with one or more substituents independently selected from a substituent group; or

R 7 and R 8 , together with the nitrogen to which they are bonded, form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl, wherein the substituted heterocycloalkyl or substituted heteroaryl is substituted with one or more substituents independently selected from a substituent group; or

R 7a and R 8s , together with the nitrogen to which they are bonded, form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl, wherein the substituted heterocycloalkyl or substituted heteroaryl is substituted with one or more substituents independently selected from a substituent group; or

R 7b and R 8b , together with the nitrogen to which they are bonded, form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl, wherein the substituted heterocycloalkyl or substituted heteroaryl is substituted with one or more substituents independently selected from a substituent group;

each R 11 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 12 -substituted or unsubstituted alkyl, R 12 -substituted or unsubstituted heteroalkyl, R 12 -substituted or unsubstituted cycloalkyl, R 12 -substituted or unsubstituted heterocycloalkyl, R 12 -substituted or unsubstituted aryl, or R 12 -substituted or unsubstituted heteroaryl;

each R 12 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 13 -substituted or unsubstituted alkyl, R 13 -substituted or unsubstituted heteroalkyl, R 13 -substituted or unsubstituted cycloalkyl, R 13 -substituted or unsubstituted heterocycloalkyl, R 13 -substituted or unsubstituted aryl, or R 13 -substituted or unsubstituted heteroaryl;

each R 13 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl, unsubstituted heteroalkyl, cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl;

each R 14 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 15 -substituted or unsubstituted alkyl, R 15 -substituted or unsubstituted heteroalkyl, R 15 -substituted or unsubstituted cycloalkyl, R 15 -substituted or unsubstituted heterocycloalkyl, R 15 -substituted or unsubstituted aryl, or R 15 -substituted or unsubstituted heteroaryl;

each R 15 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 16 -substituted or unsubstituted alkyl, R 16 -substituted or unsubstituted heteroalkyl, R 16 -substituted or unsubstituted cycloalkyl, R 16 -substituted or unsubstituted heterocycloalkyl, R 16 -substituted or unsubstituted aryl, or R 16 -substituted or unsubstituted heteroaryl;

each R 16 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl;

each R 17 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 18 -substituted or unsubstituted alkyl, R 18 -substituted or unsubstituted heteroalkyl, R 18 -substituted or unsubstituted cycloalkyl, R 18 -substituted or unsubstituted heterocycloalkyl, R 18 -substituted or unsubstituted aryl, or R 18 -substituted or unsubstituted heteroaryl;

each R 18 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 19 -substituted or unsubstituted alkyl, R 19 -substituted or unsubstituted heteroalkyl, R 19 -substituted or unsubstituted cycloalkyl, R 19 -substituted or unsubstituted heterocycloalkyl, R 19 -substituted or unsubstituted aryl, or R 19 -substituted or unsubstituted heteroaryl;

each R 19 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl;

each R 41 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 42 -substituted or unsubstituted alkyl, R 42 -substituted or unsubstituted heteroalkyl, R 42 -substituted or unsubstituted cycloalkyl, R 42 -substituted or unsubstituted heterocycloalkyl, R 42 -substituted or unsubstituted aryl, or R 42 -substituted or unsubstituted heteroaryl;

each R 42 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 43 -substituted or unsubstituted alkyl, R 43 -substituted or unsubstituted heteroalkyl, R 43 -substituted or unsubstituted cycloalkyl, R 43 -substituted or unsubstituted heterocycloalkyl, R 43 -substituted or unsubstituted aryl, or R 43 -substituted or unsubstituted heteroaryl;

each R 43 is independently oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl;

each occurrence of X, X a , and X b is independently a halogen;

each occurrence of m, m1, and m2 is independently 1 or 2;

each occurrence of n, n1, and n2 is independently 0, 1, 2, 3, or 4;

each occurrence of v, v1, and v2 is independently 1 or 2; and

z is 0, 1, or 2;

wherein each substituent group is independently selected from the group consisting of:

(A) oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , —NHS(O) 2 CH 3 , —N 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; and

(B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each independently substituted with one or more substituents independently selected from the group consisting of:

(i) oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , —NHS(O) 2 CH 3 , —N 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; and

(ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each independently substituted with one or more substituents independently selected from the group consisting of:

(a) oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , —NHS(O) 2 CH 3 , —N 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; and

(b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each independently substituted with one or more substituents independently selected from the group consisting of oxo, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , —NHS(O) 2 CH 3 , —N 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein ring A is R 41 -substituted or unsubstituted arylene, or R 41 -substituted or unsubstituted heteroarylene.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1 is a bond or unsubstituted methylene.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 1 is —S(O) n R 10 ;

R 10 is substituted or unsubstituted aryl; and

n is 2.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is R 11 -substituted alkyl, R 11 -substituted or unsubstituted cycloalkyl, R 11 -substituted or unsubstituted heterocycloalkyl, R 11 -substituted aryl, or R 11 -substituted or unsubstituted heteroaryl.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, R 14 -substituted or unsubstituted alkyl, R 14 -substituted or unsubstituted heteroalkyl, R 14 -substituted or unsubstituted cycloalkyl, R 14 -substituted or unsubstituted heterocycloalkyl, R 14 -substituted or unsubstituted aryl, or R 14 -substituted or unsubstituted heteroaryl.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is R 14 -substituted or unsubstituted cycloalkyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 3 is independently hydrogen, halogen, R 17 -substituted or unsubstituted alkyl, R 17 -substituted or unsubstituted heteroalkyl, R 17 -substituted or unsubstituted cycloalkyl, R 17 -substituted or unsubstituted heterocycloalkyl, R 17 -substituted or unsubstituted aryl, or R 17 -substituted or unsubstituted heteroaryl.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 3 is independently hydrogen.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 4 is hydrogen; and

R 5 is hydrogen.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6a is hydrogen.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

13. A method for modulating the activity of an inositol-requiring enzyme 1 protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , wherein the subject suffers from a disease selected from the group consisting of cancer, a demyelinating disease, diabetes, an eye disease, a fibrotic disease, and a neurodegenerative disease.

15. The method of claim 14 , wherein the cancer is multiple myeloma.

16. The method of claim 14 , wherein the demyelinating disease is selected from the group consisting of Charcot-Marie-Tooth disease, multiple sclerosis, Pelizaeus-Merzbacher disease, transverse myelitis, and Wolfram syndrome.

17. The method of claim 14 , wherein the diabetes is type I diabetes or type II diabetes.

18. The method of claim 14 , wherein the eye disease is selected from the group consisting of macular degeneration, retinal degeneration, retinitis pigmentosa, and Wolfram syndrome.

19. The method of claim 14 , wherein the fibrotic disease is selected from the group consisting of acetaminophen liver toxicity, cardiac hypertrophy, cirrhosis, heart failure, hepatic fibrosis, hepatitis C liver disease, hepatosteatosis, idiopathic pulmonary fibrosis, and myocardial infarction.

20. The method of claim 14 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, macular degeneration, Parkinson's disease, a prion disease, retinal degeneration, and retinitis pigmentosa.

21. The method of claim 20 , wherein the prion disease is selected from the group consisting of Creutzfeldt-Jakob disease and Kuru.

22. A compound having the formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

L 1 is a bond or unsubstituted C 1 -C 5 alkylene;

L 2 is —NR 6a —;

R 1 is —S(O) n R 10 ;

R 2 is hydrogen, halogen, —CX a 3 , —CN, —S(O) 2 Cl, —S(O) n1 R 10a , —S(O) v1 NR 7a R 8a , —NHNH 2 , —ONR 7a R 8a , —NHC(O)NHNH 2 , —NHC(O)NR 7a R 8a , —N(O) m1 , —NR 7a R 8a , —C(O)R 9a , —C(O)OR 9a , —C(O)NR 7a R 8a , —OR 10a , NR 7a S(O) n1 R 10a , —NR 7a C(O)R 9a , —NR 7a C(O)OR 9a , —NR 7a OR 9a , —OCX a 3 , —OCHX a 2 , R 14 -substituted or unsubstituted alkyl, R 14 -substituted or unsubstituted heteroalkyl, R 14 -substituted or unsubstituted cycloalkyl, R 14 -substituted or unsubstituted heterocycloalkyl, R 14 -substituted or unsubstituted aryl, or R 14 -substituted or unsubstituted heteroaryl;

R 4 is hydrogen or unsubstituted C 1 -C 6 alkyl;

R 5 is hydrogen or unsubstituted C 1 -C 6 alkyl;

R 6a , R 7a , R 8a , R 9a , R 10a , R 7b , R 8b , R 9b , R 10b , and R 10 are each independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with one or more substituents independently selected from the group consisting of halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , —NHS(O) 2 CH 3 , —N 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; or

R 7a and R 8a , together with the nitrogen atom to which they are bonded, form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl, wherein the substituted heterocycloalkyl or substituted heteroaryl is substituted with one or more substituents independently selected from the group consisting of halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , —NHS(O) 2 CH 3 , —N 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; or

R 7b and R 8b , together with the nitrogen atom to which they are bonded, form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl, wherein the substituted heterocycloalkyl or substituted heteroaryl is substituted with one or more substituents independently selected from the group consisting of halogen, —CF 3 , —CN, —OH, —NH 2 , —C(O)OH, —C(O)NH 2 , —NO 2 , —SH, —S(O) 2 Cl, —S(O) 3 H, —S(O) 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHS(O) 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , —NHS(O) 2 CH 3 , —N 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl;

each occurrence of X a and X b is independently a halogen;

each occurrence of m1 and m2 is independently 1 or 2;

each occurrence of n, n1, and n2 is independently 0, 1, 2, or 3;

each occurrence of v1 and v2 is independently 1 or 2; and

z is 0, 1, or 2.

23. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein ring A is R 41 -substituted or unsubstituted arylene, or R 41 -substituted or unsubstituted heteroarylene.

24. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein L 1 is a bond or unsubstituted methylene.

25. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein L 1 is a bond.

26. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, R 14 -substituted or unsubstituted alkyl, R 14 -substituted or unsubstituted heteroalkyl, R 14 -substituted or unsubstituted cycloalkyl, R 14 -substituted or unsubstituted heterocycloalkyl, R 14 -substituted or unsubstituted aryl, or R 14 -substituted or unsubstituted heteroaryl.

27. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein R 2 is R 14 -substituted or unsubstituted cycloalkyl.

28. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein each R 3 is independently hydrogen, halogen, R 17 -substituted or unsubstituted alkyl, R 17 -substituted or unsubstituted heteroalkyl, R 17 -substituted or unsubstituted cycloalkyl, R 17 -substituted or unsubstituted heterocycloalkyl, R 17 -substituted or unsubstituted aryl, or R 17 -substituted or unsubstituted heteroaryl.

29. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein each R 3 is independently hydrogen.

30. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein:

R 4 is hydrogen; and

R 5 is hydrogen.

31. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein R 6a is hydrogen.

32. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein:

R 10 is substituted or unsubstituted aryl; and

n is 2.

33. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 22 , or a pharmaceutically acceptable salt thereof.

34. A method for modulating the activity of an inositol-requiring enzyme 1 protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 22 , or a pharmaceutically acceptable salt thereof.

35. The method of claim 34 , wherein the subject suffers from a disease selected from the group consisting of cancer, a demyelinating disease, diabetes, an eye disease, a fibrotic disease, and a neurodegenerative disease.

36. The method of claim 35 , wherein the cancer is multiple myeloma.

37. The method of claim 35 , wherein the demyelinating disease is selected from the group consisting of Charcot-Marie-Tooth disease, multiple sclerosis, Pelizaeus-Merzbacher disease, transverse myelitis, and Wolfram syndrome.

38. The method of claim 35 , wherein the diabetes is type I diabetes or type II diabetes.

39. The method of claim 35 , wherein the eye disease is selected from the group consisting of macular degeneration, retinal degeneration, retinitis pigmentosa, and Wolfram syndrome.

40. The method of claim 35 , wherein the fibrotic disease is selected from the group consisting of acetaminophen liver toxicity, cardiac hypertrophy, cirrhosis, heart failure, hepatic fibrosis, hepatitis C liver disease, hepatosteatosis, idiopathic pulmonary fibrosis, and myocardial infarction.

41. The method of claim 35 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, macular degeneration, Parkinson's disease, a prion disease, retinal degeneration, and retinitis pigmentosa.

42. The method of claim 41 , wherein the prion disease is selected from the group consisting of Creutzfeldt-Jakob disease and Kuru.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2018

From: OAKES, SCOTT A.; PAPA, FEROZ R.; WANG, LIKUN; BACKES, BRADLEY J.

To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Reel/Frame 047069/0041 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2018

From: MALY, DUSTIN J.; PERERA, GAYANI

To: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Reel/Frame 047069/0309 →

Continuity (6)

Continuation 14670088 · Mar 26, 2015

Continuation PCTUS2013062039 · Sep 26, 2013

Provisional Application 61706037 · Sep 26, 2012

Provisional Application 61783965 · Mar 14, 2013

Provisional Application 61831088 · Jun 4, 2013

Related Publication 20190084989A1 · Mar 21, 2019

Cited By (1)

US 12,331,054